Announcements Trials

Browse Landscape

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Papillomavirus Infections 9 Uterine Cervical Neoplasms 4 Neuroendocrine Tumors 4 Autoimmune Diseases 3 Prostatic Neoplasms 2 Neoplasms 2 Abortion, Spontaneous 2 Recurrence 1 Ovarian Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Neuroblastoma 1 Neoplastic Cells, Circulating 1 Neoplasm Metastasis 1 Myasthenia Gravis 1 Lymphohistiocytosis, Hemophagocytic 1 Lung Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1

Interventions

pembrolizumab 80 Nivolumab 60 Sunitinib 59 Sorafenib 36 Everolimus 32 pazopanib 30 Axitinib 27 cabozantinib 25 Ipilimumab 24 Bevacizumab 24 atezolizumab 20 belzutifan 19 lenvatinib 16 avelumab 13 Paclitaxel 10 Docetaxel 9 temsirolimus 8 Cyclophosphamide 8 spartalizumab 7 fludarabine 7 Interleukin-2 7 Interferon alpha-2 7 tivozanib 6 durvalumab 6 Cetuximab 6 cemiplimab 5 aldesleukin 5 Ramucirumab 5 CB-839 5 bempegaldesleukin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Carcinoma, Renal Cell × Data Collection × Clear all

NCT03419572 2022-08-15

CASSIOPE

Ipsen

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡